Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its late-stage product candidate, voxelotor (GBT440), for the treatment of sickle cell disease. Source
No articles found.
Theravance Biopharma is a diversified biopharmaceutical company with the core purp...
Theravance Biopharma is a diversified biopharma...
Founded in 2009, Clovis Oncology (NASDAQ: CLVS) is a commercial stage biotechnolog...
Founded in 2009, Clovis Oncology (NASDAQ: CLVS)...
A global leader in DNA sequencing and array-based technologies, Illumina is fuelin...
A global leader in DNA sequencing and array-bas...
Oncolytics is focused on obtaining regulatory approval for pelareorep for metastat...
Oncolytics is focused on obtaining regulatory a...
Cue Biopharma is an innovative clinical stage immunotherapy company developing a n...
Cue Biopharma is an innovative clinical stage i...
CytoDyn is a publicly traded late stage biotechnology company developing innovativ...
CytoDyn is a publicly traded late stage biotech...
Spectrum Pharmaceuticals is a leading biotechnology company with a focus in Oncolo...
Spectrum Pharmaceuticals is a leading biotechno...
Join the National Investor Network and get the latest information with your interests in mind.